You are on page 1of 10

Series

Tuberculosis 6 New vaccines for tuberculosis


Stefan H E Kaufmann, Gregory Hussey, Paul-Henri Lambert
Lancet 2010; 375: 211019 Published Online May 19, 2010 DOI:10.1016/S01406736(10)60393-5 See Online/Comment DOI:10.1016/S01406736(10)60580-6 This is the sixth in a Series of eight papers about tuberculosis Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany (Prof S H E Kaufmann PhD); Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa (Prof G Hussey MD); and Centre Medical Universitaire, Centre of Vaccinology, Geneva, Switzerland (P-H Lambert MD) Correspondence to: Prof Stefan H E Kaufmann, Department of Immunology, Max Planck Institute for Infection Biology, Charitplatz 1, 10117 Berlin, Germany kaufmann@mpiib-berlin.mpg. de

New vaccines are urgently needed if we want to reach the goal of substantially reducing the incidence of tuberculosis by 2050. Despite a steady increase in funding over the past decade, there is still a striking nancial shortfall for vaccine research and development for tuberculosis. Yet, around ten vaccine candidates have left the laboratory stage and entered clinical trials. These vaccines are either aimed at replacing the present vaccine, BCG, or at enhancing immunity induced by BCG. However, these pre-exposure candidates are designed for prevention of disease and will therefore neither eradicate the pathogen, nor prevent stable infection. Long-term vaccination strategies need to target these more ambitious goals. Even though vaccine development will have a price, the return of investment will greatly exceed original costs.

Introduction
Better understanding of immunological mechanisms can form the basis for rational design of new vaccination strategies against tuberculosis.1,2 Latent infection with Mycobacterium tuberculosis is actively controlled by the immune response and once immunity wanes, reactivation occurs, which leads to active tuberculosis disease. The quality and magnitude of the immune response, therefore, decides whether the infected individual remains healthy for life, despite harbouring the pathogen, or whether infection transforms into disease. Successful control of M tuberculosis occurs in 90% of the 2 billion infected individuals worldwide, whereas 10% will develop active disease.3,4 The importance of the immune response in controlling M tuberculosis is further emphasised by the substantially increased risk of tuberculosis disease in individuals co-infected with M tuberculosis and HIV. In coinfected individuals, 10% lifetime risk of disease outbreak is increased to a 10% risk of disease outbreak within the rst year of co-infection.1 The pathology of tuberculosis ie, destruction of aected lung areashas a pronounced immunological component. Thus, solid granulomas, which contain M tuberculosis and impair functions of aected tissue sites, and necrotic and caseous lesions, which destroy substantial areas of the lung, are the result

of concurrent damage of the immune response in tuberculosis.5 Many successful vaccines have been developed through trial and error, not least the BCG vaccine, which was developed between 1906 and 1919 by attenuation of the virulent Mycobacterium bovis, but without any immunological insights.6,7 BCG protects against severe forms of tuberculosis in newborn babies, as originally proposed by its discoverers Albert Calmette and Camille Gurin.6 However, the present regimen of BCG vaccination soon after birth has little or no eect
Key messages The present BCG vaccination regimen protects newborn babies (not adults) against severe tuberculosis, has a proven safety record after more than 4 billion administrations, but faces safety issues in infants with HIV infection. Protection induced by BCG vaccination against adolescent and adult tuberculosis, the most prevalent form of the disease, is insucient. New vaccines can contribute to the ambitious goal of reducing the yearly incidence of tuberculosis to less than one new case per million population by 2050. 11 vaccine candidates have entered clinical trials: most are pre-exposure vaccines and will most likely prevent tuberculosis disease. They are intended to either replace BCG (recombinant live vaccines) or to be given after BCG prime as boosters (either protein adjuvant formulations or recombinant viral carriers). Post-exposure vaccines are also needed and, ultimately, vaccines are needed that either prevent infection or achieve sterile eradication. Vaccine trial sites with appropriate infrastructure are urgently needed. After decades of inactivity, research and development for tuberculosis vaccines is slowly increasing, although there is still a substantial shortfall in funding. New partnerships and incentives need to be created.

Search strategy and selection criteria We searched PubMed for publications containing the terms vaccination, immune response, therapy, prevention, HIV/AIDS, dormancy, latency, tuberculosis, mycobacterium, BCG, vaccine safety, clinical trials, or biomarkers. Only English language papers were reviewed where appropriate. We mainly selected publications from the past 10 years, but did not exclude relevant older publications. Additionally, we searched reference lists of these publications for relevant articles. We also included personal knowledge on the topic. Finally, we used information published by Treatment Action Group, Stop TB Partnership, WHO, and George Institute for International Health.

2110

www.thelancet.com Vol 375 June 12, 2010

Series

on the rate of pulmonary disease in adults. The worldwide appearance of HIV in the 1980s was followed by a re-emergence of tuberculosis. Hence, there is an urgent need to exploit our knowledge of basic immunology for the rational development of new vaccines against tuberculosis.3,8,9 An overview of the immune response as it relates to tuberculosis vaccine development is shown in gure 1.

BCG
BCG vaccination has been part of the Expanded Programme on Immunization since 1974, with coverage in infants exceeding 80%. The vaccines safety record after more than 4 billion administrations is as impressive as its low cost of US$010020 per dose of product. Serious adverse events after BCG vaccination in individuals without HIV infection are rare. However, the risk of disseminated BCG disease in HIV-infected infants is substantially higher than the risk in infants without HIV infection.26,27 This nding led the WHO Global Advisory Committee on Vaccine Safety to recommend that the BCG vaccine should not be used in children diagnosed as HIV positive, even though such an approach will be dicult to implement.28,29 Recent studies have also shown that HIV infection severely impairs the BCG-specic T-cell response in infants.30 BCG might therefore provide little, if any, vaccine-related benet in HIV-infected infants. Despite its widespread use in newborn babies, BCG does not prevent adult pulmonary disease satisfactorily and therefore has not reduced the global burden of tuberculosis. This nding probably reects a lack of eectiveness in adults, especially in the context of early exposure to environmental mycobacteria.31 All currently developed vaccination strategies for tuberculosis involve vaccination with a viable vaccine, either as prime for a subunit boost or as replacement for BCG, and particular care needs to be given to safety issues in individuals with HIV infection. At this stage, BCG still represents an excellent basis for newly developed prime-boost strategies. However, in the near future, its replacement by a safer product for priming will have to be considered. Tuberculosis mainly aects poor, marginalised, and socially disadvantaged individuals and communities, including those who are malnourished, immunocompromised, homeless, displaced, imprisoned, and of specic ethnic minorities.32 However, the specic causal pathways linking these factors to reduced resistance or increased disease risk are not fully understood. Resistance and susceptibility to tuberculosis are aected by a range of mycobacterial, host, social, and environmental factors. Countries with the highest rates of tuberculosis disease are those in which poverty, malnutrition, micronutrient deciencies, non-tuberculous mycobacterial infections, and intestinal parasitic infestation are prevalent, and where the likelihood of reinfection from repeated exposure to infected individuals is high.33
www.thelancet.com Vol 375 June 12, 2010

Non-tuberculous mycobacteria are common pathogens and commensal organisms in developing countries. Exposure to non-tuberculous mycobacteria can aect the immune response induced by BCG and possibly also by novel tuberculosis vaccines.34 Eects include induction of antimycobacterial immunity that is not improved after subsequent immunisation (sometimes called masking) and induction of antimycobacterial immunity that fails to provide protection and impairs induction of an adequate immune response after subsequent vaccination (blocking). Both mechanisms are not mutually exclusive. Helminth infection might increase the occurrence of tuberculosis disease or compromise the eectiveness of BCG vaccination.35 The suggested mechanism for this association is attenuation of the protective T-helper (Th) 1 immune responses induced by vaccination, which might be caused by polarisation of host immunity towards a Th2 prole, T-cell exhaustion, or increased regulatory T-cell (Treg) activity (gure 1).

For more information about the Expanded Programme on Immunization see http://www. who.int/immunization_delivery/ en

Novel vaccination strategies


To reduce the global burden of disease, new vaccination strategies (gure 2) against tuberculosis need to induce a more ecient immunity than that achieved with BCG vaccine, not only in infants but also in adolescents and adults. In infants, an optimum vaccine would fully prevent initial infection. Present vaccination candidates are intended to only reduce the initial bacterial burden with containment of remaining M tuberculosis organisms (gure 2).36 Immunologically contained M tuberculosis is thought to transform from a metabolically active replicating form into a dormant form with minimum metabolism and absent or low replication that can lead to disease reactivation at a later stage.3739 Therefore, appropriate postexposure vaccines are needed to target dormant M tuberculosis and prevent reactivation. Post-exposure vaccines should also prevent reinfection of individuals with latent infection, notably in regions with high tuberculosis prevalence.

Present candidates
The crucial underlying mechanism of action of present vaccine candidates is stimulation of Th1 cells, which activate antimycobacterial capacities in macrophages (gure 1).3 Of central importance are memory T cells that produce several cytokines concomitantlynotably, interferon , tumour necrosis factor, and interleukin 2.23 Additionally, CD8 T cells directly attack M tuberculosis by means of perforin and granulysin,20 and Th17 cells17 support Th1 responses.

Live mycobacterial vaccines


Live mycobacterial vaccines are based either on improvement of BCG vaccine through addition of relevant genes or on attenuation of M tuberculosis through deletion of virulence genes (gure 2, table). Because of
2111

Series

M
CD8 CTL

IFN

Lysis Protection CD8 TM Solid granuloma

Lysis

IFN

CD8 Te M tuberculosis PRR Cross-priming

CD8 TM

Latent infection

Exhaustion CD8

M
MHC I PNG

M
T

T M

Protection

DC MHC II CD4 Th17 M tuberculosis PRR DC MHC I Th2 Direct presentation CD8 IL4 IL10 TGF Treg Suppression T Active disease M MHC II CD4 CD4 Te IL17 IFN IL2 IFN TNF Th1 TM Caseous granuloma

Th1

Figure 1: Overview of the immune response in tuberculosis Control of Mycobacterium tuberculosis is mainly the result of productive teamwork between T-cell populations and macrophages (M ).10 M tuberculosis survives within macrophages and dendritic cells (DCs) inside the phagosomal compartment.11 Gene products of MHC class II are loaded with mycobacterial peptides that are presented to CD4 T cells. CD8 T-cell stimulation requires loading of MHC I molecules by mycobacterial peptides in the cytosol, either by egression of mycobacterial antigens into the cytosol12 or cross-priming, by which macrophages release apoptotic bodies carrying mycobacterial peptides.13 These vesicles are taken up by DCs and peptides presented. The CD4 T-helper (Th) cells polarise into dierent subsets.14 DCs and macrophages express pattern recognition receptors (PRR),15,16 which sense molecular patterns on pathogens. Th1 cells produce interleukin (IL) 2 for T-cell activation, interferon (IFN), or tumour necrosis factor (TNF) for macrophage activation. Th17 cells, which activate polymorphonuclear granulocytes (PNGs), contribute to the early formation of protective immunity in the lung after vaccination.10,17,18 Th2 cells and regulatory T cells (Treg) counter-regulate Th1-mediated protection via IL4, transforming growth factor (TGF ), or IL10.19 CD8 T cells produce IFN and TNF, which activate macrophages.2,10 They also act as cytolytic T lymphocytes (CTL) by secreting perforin and granulysin, which lyse host cells and directly attack M tuberculosis.20 These eector T cells (Te) are succeeded by memory T cells (TM).21,22 TM cells produce multiple cytokines, notably IL2, IFN, and TNF.2224 During active containment in solid granuloma, M tuberculosis recesses into a dormant stage and is immune to attack. Exhaustion of T cells is mediated by interactions between T cells and DCs through members of the programmed death 1 system.25 Treg cells secrete IL10 and TGF , which suppress Th1.19 This process allows resuscitation of M tuberculosis, which leads to granuloma caseation and active disease. B=B cell.

the widespread use of BCG vaccine, it can only be replaced by a vaccine that is safer or more eective, or both. Assessment of the safety and ecacy of new vaccines will require careful analyses with assays and trials that are harmonised as much as possible. Two improved recombinant BCG (rBCG) vaccines have already started initial clinical assessment. Results of preclinical studies suggested that both replacement vaccines were more potent and safer than the currently used BCG vaccine.40,41 rBCG30 was the rst vaccine candidate shown to induce substantially greater protection than did parental BCG in dierent animal models. The second vaccine, rBCGureC:Hly (VPM1002), is a recombinant strain that
2112

secretes listeriolysin produced by Listeria monocytogenes and sustains an acidic phagosomal pH for optimum listeriolysin activity. Perforation of the phagosomal membrane probably promotes antigen translocation into the cytoplasm and facilitates cross-priming and stimulation of Th17 cells through increased apoptosis.4143 Other live mycobacterial vaccines are expected to enter clinical trials in the next few years.36 Attention has focused on constructs resulting from the genetic attenuation of M tuberculosis. The most advanced of these is the MTBVAC01 vaccine that was constructed by disruption of the transcriptional regulator gene phoP, which is associated with M tuberculosis virulence, and the fadD26 genes.44,45
www.thelancet.com Vol 375 June 12, 2010

Series

A
Severity of disease Pre-exposure vaccination with BCG

B
Severity of disease Pre-exposure prime with BCG Pre-exposure boost with subunit Infection Active disease Miliary tuberculosis Reactivation, reinfection Pulmonary tuberculosis Latent infection Miliary tuberculosis Reactivation, Pulmonary reinfection tuberculosis Vaccinated Unvaccinated

Infection Active disease Latent infection

05

530

>30

05

530

>30

C
Severity of disease Pre-exposure prime with BCG Post-exposure boost with subunit

D
Severity of disease Pre-exposure vaccination with superior BCG replacement

Infection Active disease Latent infection Miliary tuberculosis

Active disease Reactivation, reinfection Pulmonary tuberculosis Latent infection Miliary tuberculosis Reactivation, Pulmonary reinfection tuberculosis

05

530

>30

05

530

>30

E
Severity of disease Infection Active disease Latent infection Reactivation, reinfection Therapeutic vaccination with killed mycobacteria in adjunct to chemotherapy

F
Severity of disease Pre-exposure prime with superior BCG replacement Pre-exposure boost with subunit Post-exposure boost with subunit Infection

Pulmonary tuberculosis

Active disease Latent infection Reinfection Pulmonary tuberculosis

05

530

>30

05

530

>30

G
Severity of disease Infection Active disease Latent infection Post-exposure prime with superior BCG replacement Post-exposure boost with subunit Pulmonary tuberculosis Reactivation, reinfection

H
Severity of disease Pre-exposure vaccination against infection

Booster vaccination against infection Infection Active disease Latent infection Miliary tuberculosis Reinfection

Pulmonary tuberculosis

05

530 Time (years)

>30

05

530 Time (years)

>30

Figure 2: Dierent vaccination strategies Present strategy: (A) pre-exposure vaccination with BCG protects against early childhood tuberculosis but does not eradicate Mycobacterium tuberculosis. Future vaccination strategies: (B) pre-exposure boost with subunit vaccine in children primed with BCG to prevent tuberculosis in early childhood and to delay tuberculosis disease outbreak in adults; (C) post-exposure boost with subunit vaccine in adults who had been primed with BCG during early childhood to delay tuberculosis disease outbreak in adults; (D) pre-exposure vaccination with superior BCG replacement to prevent tuberculosis in early childhood and to delay tuberculosis disease outbreak in adults; (E) therapeutic vaccination in adjunct to chemotherapy in patients with active tuberculosis; (F) heterologous prime-boost vaccination with superior BCG replacement and subunit vaccine, to achieve sterile eradication; (G) heterologous prime-boost vaccination in individuals with latent infection by prime with superior BCG replacement and subunit vaccine boost to prevent tuberculosis disease outbreak; and (H) pre-exposure vaccination to prevent stable infection with M tuberculosis.

www.thelancet.com Vol 375 June 12, 2010

2113

Series

Description MVA85A Attenuated strain of vaccinia expressing Ag85A BCG overexpressing Ag85B Non-replicating Ad35 expressing Ag85A, Ag85B, and TB10.4 Non-replicating Ad5 expressing Ag85A Recombinant fusion (Mtb39 and Mtb32) in AS02 and AS01 adjuvant systems Recombinant fusion of Ag85B-ESAT-6 in IC31 adjuvant Recombinant fusion of Ag85B-ESAT-6 in CAF01 adjuvant Recombinant fusion of Ag85B-TB10.4 in IC31 adjuvant BCG with an endosome escape mechanism Detoxied M tuberculosis in liposomes Inactivated M vaccae

Developmental stage Phase 1 completed and phase 2 continuing; phase 2b in infants started Phase 1 completed Phases 1 and 2 continuing Phase 1 Phases 1 and 2 completed; additional trials continuing Phase 1 completed Phase 1 continuing Phase 1 completed Phase 1 completed Phase 1 completed Phase 3 completed

Sponsor or funder Wellcome Trust, Aeras, Emergent BioSolutions University of California, Los Angeles; Aeras Aeras McMaster University GlaxoSmithKline, Aeras, Tuberculosis Vaccine Initiative Statens Serum Institut, Tuberculosis Vaccine Initiative Statens Serum Institut, Tuberculosis Vaccine Initiative Statens Serum Institut, Aeras Vakzine Projekt Management, Tuberculosis Vaccine Initiative, Max Planck Institut Archivel Farma National Institutes of Health

rBCG30 AERAS-402 AdAg85A M72 H1-IC31 H1-CAF01 H4-IC31 (AERAS-404) rBCGUreC:Hly (VPM1002) RUTI M vaccae

MVA=modied vaccinia Ankara. Ag=antigen. Ad=adenovirus. AS=adjuvant system. ESAT-6=early secretory antigenic target 6. CAF=cationic adjuvant formulation. Hly=haemolysin. *11 new tuberculosis vaccines that have gone into clinical trials. Two of them, MVA85A and AERAS-402 Mycobacterium vaccae, have gone into phase 2 trials and one, M vaccae, has completed a phase 3 trial.

Table: New tuberculosis vaccines in clinical trials*

Another attenuated M tuberculosis vaccine candidate is M tuberculosis RD1 panCD.46

Subunit and live vector-based vaccines that boost BCG prime


Several vaccines use a prime-boost strategy to complement the immune response induced by BCG (gure 2, table). Subunit vaccine candidates are based on antigens that are recognised by T cells from patients with latent infection or whose tuberculosis has been cured. Two types of products have been developed: recombinant fusion proteins consisting of two or three dominant M tuberculosis or BCG antigens and live viral vectors that express one or several mycobacterial proteins. Recombinant protein vaccines can be given repeatedly but need an adjuvant that promotes Th1 immune responses. Live viral vector vaccines do not require adjuvant but can be inhibited by previous exposure to the vector. They trigger a Th1-dominated immune response to the expressed heterologous antigen and induce CD8 T-cell responses. All developed prime-boost candidate vaccines protect mice and guineapigs to a similar level to that obtained with BCG vaccine; several have also been shown to be protective in non-human primates.45 Ag85B-ESAT-6 (H1) candidate vaccine was designed with a strong Th1 adjuvant, IC31 (Intercell, Vienna, Austria), which is a mixture of oligodeoxynucleotides and polycationic aminoacids.47,48 This vaccine has been assessed in two phase 1 clinical trials. It seems to be well tolerated, without any serious adverse reactions, and highly immunogenic in human beings.49 It induces a strong persisting Th1 response to the Ag85B protein of
2114

M tuberculosis. The transitory response to early secretory antigenic target 6 (ESAT-6) does not seem to interfere with ESAT-6-based diagnostic assays done a few months after immunisation.50 Ag85B-TB-10.4 (H4, AERAS-404) was developed as an alternative to Ag85B-ESAT-6.51 In this fusion protein, ESAT-6 was replaced by TB-10.4 to reduce the putative risk of interference with ESAT-6-based diagnostic assays. M72 is a hybrid protein that is formulated in a vaccine adjuvant system containing monophosphoryl lipid A and QS21. This vaccine had acceptable tolerability and induced profound T-cell responses in healthy adults.52 MVA85A is a recombinant, replication-decient vaccinia virus that expresses Ag85A. This vaccine was eective in animal models. In initial trials in human beings, the vaccine induced strong Th1 responses and boosted previous immunity.53,54 Previous vaccination with vaccinia might reduce the eectiveness of vaccines that use this vector.55 Ad35 (AERAS-402) and AdAg85A are replicationdecient (E1-deleted) recombinant adenoviruses.56,57 These vaccines are of particular interest for their ability to induce CD8 T-cell responses. However, there is evidence that previous natural exposure to a homologous or cross-reacting strain of adenovirus might hamper responses to adenovirus-based vaccines.58 Adenovirus 5 is highly prevalent in human populations and hence the eectiveness of the vaccine could be aected by preexisting antibodies. Adenovirus 35 vaccines might be less aected by this limitation since this serotype has a fairly low prevalence (ranging from 5% in developed countries to 20% in Africa).
www.thelancet.com Vol 375 June 12, 2010

Series

Heparin-binding haemagglutinin (HBHA) is an interesting but challenging vaccine candidate because the protein is highly methylated. This structure renders it dicult to produce the protein as a recombinant product in an unrelated expression system. HBHA is a mycobacterial surface protein that interacts specically with non-phagocytic cells.59,60 HBHA vaccination boosted BCG-induced protection in mice.61,62 The protective value of the vaccine, and its antigenicity in patients with latent infection, strongly depend on the methylation pattern of HBHA.

Killed whole bacterial vaccines as adjunct


Vaccines that accelerate or complement the eects of tuberculosis chemotherapy would be most welcome. Many attempts to make such a vaccine have been made, but these have been especially cautious because of the potential risk of disease enhancement known as Kochs phenomenon.63 Two dierent approaches are now being assessed in clinical trials: one based on killed Mycobacterium vaccae and another one based on mycobacterial fragments (gure 2, table). Whole heat-killed M vaccae, an environmental saprophyte, has been tested as an immunotherapeutic agent in tuberculosis. The vaccine is usually given intradermally in a multidose series. Clinical studies show that vaccination might improve radiological and clinical outcomes, decrease time to negative sputum culture, and improve cure rate in some patients with positive-sputum culture (including patients with multidrug-resistant tuberculosis).64 Three major trials have been undertaken in Africa with discrepant outcomes.65 The DarDar phase 3 trial, a randomised, placebo-controlled, double-blind study in BCG-vaccinated patients with HIV infection, reportedly shows that this vaccine reduces the number of tuberculosis cases.66 However, at this stage, the publically available data do not allow any denitive conclusions about the potential usefulness of this approach. RUTI is another proposed therapeutic vaccine candidate.67,68 M tuberculosis is grown under stress conditions and bacilli are then fragmented, detoxied, and delivered in liposomes.

In the second strategy, use of new combinations of prime with BCG (or BCG substitutes) and new boost vaccines is aimed at achieving sterile eradication of M tuberculosis rather than containing persistence. Some of these boost vaccines might eventually be considered as replacements for BCG. Three types of vaccines have to be considered in a comprehensive tuberculosis vaccination strategy. First, BCG or, if available, a BCG replacement to prime the immune system and prepare it for subsequent subunit boost that would improve the initial level of immunity. Prime vaccination should induce memory T cells that are restimulated by boost vaccination to reach higher levels of eectiveness. In case of early tuberculosis exposure, such a vaccine would at least reduce the initial bacterial burden, slow down bacterial growth, and protect against early tuberculosis disease. Second, a subunit vaccine should be given in the next step, a few weeks to several years after BCG or its replacement, to boost and possibly reorient the BCGinduced memory response. The goal would be to increase duration of immunity and improve protection conferred by the prime event. Such boosting vaccines might have to be repeatedly administered during an individuals lifespan with changing antigen composition. Third, boost vaccines for post-exposure administration are expected to target latent infection and to clear persisting mycobacteria, or at least prevent reactivation of dormant M tuberculosis. Such vaccines could be given to adolescents and adults who have latent infection. Hybrid 56 adds the dormancy antigen Rv2660 to the antigen 85B and ESAT-6 in IC31 of the Ag85B-ESAT-6 vaccine to achieve a booster eect in individuals with latent M tuberculosis infection.36 This vaccine is due to enter clinical trials in 2010.

Distant-future candidate vaccines


The vaccine candidates that we have discussed have already entered, or will soon enter, clinical trials. Thus, the development pipeline for tuberculosis vaccines has become more active than ever before. However, the end is still not in sight, and further improvements are needed. As information ows back from phase 1 and 2 clinical trials, both ecacy and safety of the vaccine candidates tested can be rened. In parallel, rational vaccine development based on deeper insights into immunology, microbiology, and molecular genetics will be pursued. Live vaccines can be made more eective by introduction of additional antigens, such as dormancy antigens (eg, to facilitate postexposure boost vaccination of individuals with latent infection).8,69 Finally, viable vaccine candidates can be endowed with immunopotentiating activity (eg, by introduction of stimulatory cytokines that favour relevant T-cell subsets or by deletion of antiapoptotic genes to strengthen cross-priming). Improvement of subunit vaccine eectiveness involves introduction of novel adjuvants in protein vaccine formulations and selection of
2115

Near-future candidate vaccines


Vaccine candidates that are less well advanced aim to reduce tuberculosis burden by use of two strategies (gure 2). In the rst proposed strategy, post-exposure vaccines target dormant M tuberculosis and help to eliminate the pathogen during its dormant or slowly replicating phase of infection, thereby preventing later tuberculosis reactivation. There are many latency antigens; their expression in dormant mycobacteria reects the metabolic status of the organism.69 The identication of M tuberculosis stage-specic genes has been greatly aided by the development of genome-wide expression arrays.37,38 Remarkably, BCG vaccination apparently does not induce immunity to dormancy antigens, or does so only weakly.
www.thelancet.com Vol 375 June 12, 2010

Series

For more on the Stop TB Partnership see http://www. stoptb.org/

For more on biomarkers for tuberculosis see http://www. biomarkers-for-tb.net/

better viral carriers. Dierent combination strategies need to be exploited to identify the most appropriate heterologous prime-boost vaccination schedule for pre-exposure and post-exposure vaccination. Ideally, such combinations would not only delay tuberculosis reactivation, but also cause sterile eradication of M tuberculosis. In addition to continuing eorts, new strategies need to be envisioned. One such strategy would be a vaccine that prevents infection with M tuberculosis. In an era of HIV/M tuberculosis co-infection, such a vaccine would be highly desirable because weakening of vaccine-induced immunity by HIV greatly increases risk of active tuberculosis disease. One option would be the stimulation of highly eective antibodies in the lung.8 These antibodies would target M tuberculosis molecules essential for its survival and then block uptake by phagocytes, and at the same time induce humoral eector molecules that kill the pathogen. Alternatively, these antibodies would promote uptake and subsequent killing of M tuberculosis by strongly activated phagocytes and prevent uptake by non-professional phagocytes that could be misused by the organism as a safe niche. Since only few M tuberculosis organisms enter the alveolar system of the lung, this strategy warrants experimental verication. In cavitary tuberculosis disease, the burden of extracellular M tuberculosis often exceeds 10 microorganisms, which serve as a source of transmission and dissemination. Hence, future design of a therapeutic vaccine against tuberculosis could benet from stimulation of antibodies that attack M tuberculosis in the caseous detritus.

target populations of infants and adolescents in Kenya, Uganda, Mozambique, and India as a prelude to undertaking clinical trials of new tuberculosis vaccine candidates. The African sites have established a network to share experiences; support exchange visits and training in clinical research; provide guidelines for good clinical practice, good laboratory practice, and quality management; and to strengthen expertise in clinical diagnosis, microbiology, and immunology. Additional sites that meet basic requirements will certainly be needed for phase 3 trials (panel). Large-scale phase 3 clinical trials that take several years to complete will be a costly undertaking. Unfortunately, the countries that are most in need of new vaccines, and where the trial sites will be located, are those with the least ability to support these costs. The Stop TB Partnership estimates that the cost for a new tuberculosis vaccine to be licensed by 2015 is approximately $35 billion, for which there is currently a funding shortfall of over $1 billion.

Monitoring of vaccine trials


As for any new vaccine, the rst objective of initial clinical trials for new tuberculosis vaccines is to assess safety. Special attention has to be given to live vaccines in populations at risk of HIV infection. Biomarkers of immunity are of primary importance to assess vaccine responses as described in the fourth report of this Series.70 Assays measuring T-cell responses are routinely used with a particular focus on responses to peptide epitopes contained in the vaccine. Unfortunately, these assays are so far not directly correlated with protective eects of vaccination. There is hope that further characterisation of the responding T-cell populations will better reect the degree of protection. Eorts are now in progess to exploit biomics for tuberculosis biomarker design71 and to introduce functional bactericidal assays into clinical trials, as done for several bacterial vaccines (eg, meningococcal vaccines).

Clinical trial site development


Promising tuberculosis vaccine candidates will soon be entering phase 3 clinical trials, requiring the enrolment of large cohorts of 10 000 or more individuals. To generate data that can be extrapolated to countries with genetically, culturally, and environmentally diverse populations, such trials should be done in several countries in dierent regions of the world. Developing a eld site for the assessment of new tuberculosis vaccine candidates is dicult. In the absence of a well dened surrogate marker of protection, clinical studies are essential to establish ecacy and need long-term follow-up, high cohort retention, and good surveillance systems for monitoring trial endpoints such as morbidity and mortality. A major problem in tuberculosis trials in children is that there is no easily identiable and measurable clinical endpoint. At present only one site (the South African Tuberculosis Vaccine Initiative; SATVI) has the capacity to undertake phase 3 trials of tuberculosis vaccines on the African continent. Availability of multiple sites that can provide similar high standards is urgently needed. Aeraswith the technical support and advice of SATVI, and additional funding from the European Developing Countries Clinical Trials Partnership and the Research Council of Norwayhas embarked on a capacity-building programme and is supporting several cohort studies in

Ethical and regulatory issues


The target populations to be studied for phase 2 and 3 trials of tuberculosis vaccines live in areas where the disease is endemic and can generally be described as being research-naive, poorly educated, socially insecure, oppressed, and unaccustomed to insisting on their basic human rights. Poverty is endemic, unemployment rates are high, and most people subsist on less than $1 per day. To avoid violations of participants human rights, clinical trials need to be undertaken in accordance with the international ethical principles and practices that have their origin in the Declaration of Helsinki.72 Additionally, trials need to adhere to Good Clinical Practices and the applicable regulatory requirements. Many developing countries do not have regulatory authorities; where they do exist, they need to be strengthened in the areas of preclinical product review and protocol review for initial phase 1 testing of new
www.thelancet.com Vol 375 June 12, 2010

For more on SATVI see http:// www.satvi.uct.ac.za For more on Aeras see http:// www.aeras.org For more on the European Developing Countries Clinical Trials Partnership see http:// www.edctp.org/ For more on the Research Council of Norway http://www. forskningsradet.no/english/

2116

Series

Panel: Basic requirements for study sites for phase 3 trials of tuberculosis vaccines Epidemiological High rates of tuberculosis in the target population (>05% per year) Ability to detect, investigate, and document a high proportion of important health events that might occur for assessment of safety and ecacy Good surveillance system with the ability to detect each and every case of tuberculosis that occurs Clinical Ability to diagnose tuberculosis infection and disease as accurately as possible, including capacity for microbiological tuberculosis culture Competent clinical research team willing and able to prioritise tuberculosis vaccine studies Adequate referral structures for detected cases of infection and disease Immunology laboratory Ability to at least process and dispatch specimens for analysis of immunogenicity Ethics and regulatory Competent and ecient local and national ethics and regulatory authorities General Good physical infrastructure: roads, telecommunications, power, security Political stability and commitment Established relationship with the local community

tuberculosis vaccines. WHO has convened a series of meetings since 2005 to specically discuss the regulatory challenges for testing and introducing new tuberculosis vaccines in countries where the disease is endemic.73 Furthermore, WHO is exploiting ways to develop capacities at national and regional levels. Until this development occurs, the most ecient regulatory pathway is to have the rst tuberculosis vaccine phase 1 trials in countries non-endemic for tuberculosis with established regulatory authorities. Regulatory authorities in developing countries will then be more likely to accept clinical testing of tuberculosis vaccines in their regions. The informed consent process and enrolment of participants poses enormous logistical and ethical challenges. Although most participants might have a basic understanding of English, they have poor literacy skills. To resolve this problem, partnerships should be formed with local communities to assist with literacy and related issues.74

200708. 1520% of these funds was allocated specically for vaccines and 2025% for basic science, part of which was dedicated to vaccine discovery.7577 However, this amount is substantially lower than the $2 billion needed every year, over the next 10 years, to fund tuberculosis vaccine research and development. Public-private-philanthropic partnerships are becoming more common in tuberculosis vaccine research. The US National Institutes of Health and the European Commission are the major representatives of the public sector, and the Bill & Melinda Gates Foundation and the Wellcome Trust represent the philanthropic sector. Pharmaceutical companies involved in these partnerships include major rms such as GlaxoSmithKline and SanoAventis and small start-up companies such as Crucell, Intercell, and Emergent BioSolutions.77 Moreover, northsouth collaborations and capacity building have been notably strengthened by the European Developing Countries Clinical Trials Partnership and Aeras.78 Additional eorts are needed, such as targeted funding for research and development for antituberculosis drugs.32 To secure an aordable price for newly developed products, a global access strategy is requested by some funderseg, the Bill & Melinda Gates Foundation requires available and aordable access in poor countries to all products developed with Gates Foundation funding. To stimulate interest in the development of new vaccines, the World Bank, GAVI Alliance, and other stakeholders have created Advanced Market Commitments (AMC) for vaccines, which in principle guarantee purchase of a predetermined number of doses of a newly developed vaccine at an aordable xed price.79 The rst product beneting from the AMC approach is a new pneumococcal vaccine. In the past, tuberculosis vaccines have been under consideration for an AMC proposal on the basis of the calculation that a vaccine to replace BCG could avert 77 million deaths and a new boost vaccine could lead to a further 40% reduction in deaths.

For more information about the Bill & Melinda Gates Foundation see http://www. gatesfoundation.org For more information about the Wellcome Trust see http://www. wellcome.ac.uk

For more information about the GAVI Alliance see http://www. gavialliance.org

Outlook
The targets of the Stop TB Partnership are to halve tuberculosis prevalence and mortality by 2015 compared with 1990 levels, and to reduce the annual incidence of new tuberculosis cases to less than one per million population by 2050.80 These ambitious goals will only be achieved by the combined introduction of new diagnostics, drugs, and vaccines. Several predictions based on mathematical models have been used to forecast the eects of dierent scenarios. The most recent prediction calculates a reduction in tuberculosis incidence of 3952% by 2050 as a result of new pre-exposure vaccines; a reduction in incidence of 1027% from new drugs that shorten duration of treatment and are eective against drug-resistant strains; and an additional reduction of 1342% from new measures allowing reliable and fast diagnosis of tuberculosis. Combined, these three new measures could reduce tuberculosis incidence by up to
2117

Funding
An estimated $400500 million per year was available for tuberculosis research and development worldwide in
www.thelancet.com Vol 375 June 12, 2010

Series

71%.81 Incidence could be further reduced by up to 94% by mass vaccination campaigns, new post-exposure vaccines, and drugs for latent infection. Although the elimination of tuberculosis as a global public health problem by 2050 is a particularly ambitious goal, development of new intervention measures and novel vaccines could make a substantial contribution to achieving it.
Contributors All authors wrote and revised the report. All authors saw and approved the nal version. Steering committee This article is part of The Lancet Series on tuberculosis, which was developed and coordinated by Alimuddin Zumla (University College London Medical School, London, UK); Mario C Raviglione (Stop TB Department, WHO, Geneva, Switzerland); and Ben Marais (University of Stellenbosch, Stellenbosch, South Africa). Conicts of interest SHEK is co-inventor of the rBCGUreC:Hly vaccine candidate and a member of the Scientic Advisory Boards of Intercell and Vaccine Project Management. GH is the founding director of the South African Tuberculosis Vaccine Initiative (SATVI). P-HL is the Chairman of the Tuberculosis Vaccine Initiative and a member of the Aeras Vaccine Selection Advisory Committee. He is also a member of the Scientic Advisory Board of Novartis Vaccines and Diagnostics and has received consultancy fees from GlaxoSmithKline. Acknowledgments We thank M L Grossman and S Sibaei for help in preparing the report. SHEKs laboratory receives nancial support for tuberculosis vaccine research and development from EU FP6-TBVAC, FP6-MUVAPRED and FP6-PRIBOMAL, FP7-TBVIR, FP7-NEWTBVAC, and Bill & Melinda Gates Foundation Grand Challenges in Global Health GC6-74 (number 37772), of which he is also principal investigator, and GC12-82 (number 37885). GHs research group (SATVI) is funded by Aeras, the European and Developing Countries Clinical Trials Partnership, Oxford University, National Institutes of Health, and Bill & Melinda Gates Foundation Grand Challenges in Global Health GC6-74 (number 37772) and GC12-82 (number 37885). References 1 Kaufmann SHE, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 2005; 11 (suppl 4): S3344. 2 Kaufmann SHE. Envisioning future strategies for vaccination against tuberculosis. Nat Rev Immunol 2006; 6: 699704. 3 Kaufmann SHE. Recent ndings in immunology give tuberculosis vaccines a new boost. Trends Immunol 2005; 26: 66067. 4 Young D, Dye C. The development and impact of tuberculosis vaccines. Cell 2006; 124: 68387. 5 Ulrichs T, Kaufmann SHE. New insights into the function of granulomas in human tuberculosis. J Pathol 2006; 208: 26169. 6 Calmette A, Gurin C, Boquet A, Ngre L. Prophylactic vaccination against tuberculosis using BCG. Paris: Masson, 1927 (in French). 7 Kaufmann SH. Immunologys foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchniko. Nat Immunol 2008; 9: 70512. 8 Kaufmann SH. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 2007; 5: 491504. 9 Ishii KJ, Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 2007; 27: 36371. 10 Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27: 393422. 11 Russell DG. Who puts the tubercle in tuberculosis? Nat Rev Microbiol 2007; 5: 3947. 12 van der Wel N, Hava D, Houben D, et al. M tuberculosis and M leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007; 129: 128798. 13 Winau F, Hegasy G, Kaufmann SHE, Schaible UE. No life without death-apoptosis as prerequisite for T cell activation. Apoptosis 2005; 10: 70715.

14 15 16 17

18 19 20

21 22

23 24 25 26

27

28 29

30

31 32 33

34

35

36

37

38

39 40

Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 13846. Dorhoi A, Kaufmann SH. Fine-tuning of T cell responses during infection. Curr Opin Immunol 2009; 21: 36777. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783801. Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4(+) T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8: 36977. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485517. Belkaid Y, Tarbell K. Regulatory T cells in the control of hostmicroorganism interactions (*). Annu Rev Immunol 2009; 27: 55189. Stenger S, Hanson DA, Teitelbaum R, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282: 12125. Williams MA, Bevan MJ. Eector and memory CTL dierentiation. Annu Rev Immunol 2007; 25: 17192. Sallusto F, Geginat J, Lanzavecchia A. Central memory and eector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22: 74563. Foulds KE, Wu CY, Seder RA. Th1 memory: implications for vaccine development. Immunol Rev 2006; 211: 5866. Mora JR, von Andrian UH. T-cell homing specicity and plasticity: new concepts and future challenges. Trends Immunol 2006; 27: 23543. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677704. Azzopardi P, Bennett CM, Graham SM, Duke T. Bacille Calmette-Guerin vaccine-related disease in HIV-infected children: a systematic review. Int J Tuberc Lung Dis 2009; 13: 133144. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007; 25: 1418. WHO. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007; 82: 19396. Hesseling AC, Cotton MF, Marais BJ, et al. BCG and HIV reconsidered: moving the research agenda forward. Vaccine 2007; 25: 656568. Mansoor N, Scriba TJ, de Kock M, et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille CalmetteGuerin vaccine. J Infect Dis 2009; 199: 98290. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 133945. Kaufmann SHE. The new plagues: pandemics and poverty in a globalized world. London: Haus Publishing, 2009. Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the ecacy of bacillus Calmette-Guerin vaccine. Clin Infect Dis 1995; 20: 98291. Weir RE, Black GF, Nazareth B, et al. The inuence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guerin vaccination in southern England and northern Malawi. Clin Exp Immunol 2006; 146: 39099. Hatherill M, Adams V, Hughes J, et al. The potential impact of helminth infection on trials of novel tuberculosis vaccines. Vaccine 2009; 27: 474344. StopTB Partnership Working Group on New TB Vaccines. Tuberculosis vaccine candidates 2009. http://www.stoptb.org/wg/ new_vaccines/assets/documents/TB%20Vaccine%20Pipeline%20 2009.pdf (accessed Feb 19, 2010). Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression proling. Mol Microbiol 2002; 43: 71731. Voskuil MI, Schnappinger D, Visconti KC, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003; 198: 70513. Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 2001; 55: 13963. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA. A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeciency viruspositive persons is safer and more ecacious than BCG. Infect Immun 2008; 76: 520014.

2118

www.thelancet.com Vol 375 June 12, 2010

Series

41

42 43

44

45

46

47

48

49 50

51

52

53

54

55

56

57

58 59

Grode L, Seiler P, Baumann S, et al. Increased vaccine ecacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Gurin mutants that secrete listeriolysin. J Clin Invest 2005; 115: 247279. Winau F, Weber S, Sad S, et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 2006; 24: 10517. Torchinsky MB, Garaude J, Martin AP, Blander JM. Innate immune recognition of infected apoptotic cells directs T(H)17 cell dierentiation. Nature 2009; 458: 7882. Martin C, Williams A, Hernandez-Pando R, et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006; 24: 340819. Verreck FA, Vervenne RA, Kondova I, et al. MVA.85A boosting of BCG and an attenuated, phoP decient M tuberculosis vaccine both show protective ecacy against tuberculosis in rhesus macaques. PLoS One 2009; 4: e5264. Sambandamurthy VK, Derrick SC, Hsu T, et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 2006; 24: 630920. Lingnau K, Riedl K, von Gabain A. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 2007; 6: 74146. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 2006; 177: 635360. Aagaard C, Dietrich J, Doherty M, Andersen P. TB vaccines: current status and future perspectives. Immunol Cell Biol 2009; 87: 27986. van Dissel JT, Arend SM, Prins C, et al. Ag85BESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specic T cell responses in nave human volunteers. Vaccine 2010; 28: 357181. Dietrich J, Aagaard C, Leah R, et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: ecient protection and ESAT6-based sensitive monitoring of vaccine ecacy. J Immunol 2005; 174: 633239. Von Eschen K, Morrison R, Braun M, et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum Vaccin 2009; 5: 47582. McShane H, Pathan AA, Sander CR, et al. Recombinant modied vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10: 124044. Sander CR, Pathan AA, Beveridge NE, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009; 179: 72433. Rooney JF, Wohlenberg C, Cremer KJ, Moss B, Notkins AL. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and eect of revaccination. J Virol 1988; 62: 153034. Radosevic K, Wieland CW, Rodriguez A, et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007; 75: 410515. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006; 74: 463443. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006; 24: 84962. Menozzi FD, Rouse JH, Alavi M, et al. Identication of a heparinbinding hemagglutinin present in mycobacteria. J Exp Med 1996; 184: 9931001.

60

61

62

63

64

65

66

67 68

69

70

71 72

73

74

75

76

77 78 79

80 81

Pethe K, Alonso S, Biet F, et al. The heparin-binding haemagglutinin of M tuberculosis is required for extrapulmonary dissemination. Nature 2001; 412: 19094. Rouanet C, Debrie AS, Lecher S, Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 2009; 11: 9951001. Locht C, Hougardy JM, Rouanet C, Place S, Mascart F. Heparinbinding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (Edinb) 2006; 86: 30309. Rook GA, Stanford JL. The Koch phenomenon and the immunopathology of tuberculosis. Curr Top Microbiol Immunol 1996; 215: 23962. Dlugovitzky D, Fiorenza G, Farroni M, Bogue C, Stanford C, Stanford J. Immunological consequences of three doses of heatkilled Mycobacterium vaccae in the immunotherapy of tuberculosis. Respir Med 2006; 100: 107987. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004; 9: 170119. Von Reyn CF, Mtei L, Arbeit R, et al. Prevention of tuberculosis in Bacille Calmette-Gurin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24: 67585. Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 2006; 86: 27389. Vilaplana C, Montane E, Pinto S, et al. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2009; 28: 110616. Lin MY, Ottenho TH. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Biol Chem 2008; 389: 497511. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; published online May 19. DOI:10.1016/S0140-6736(10)60359-5. Parida SK, Kaufmann SH. The quest for biomarkers in tuberculosis. Drug Discov Today 2010; 15: 14857. World Medical Association. Declaration of Helsinkiethical principles for medical research involving human subjects (19642008). http://www.wma.net/en/30publications/10policies/b3/ index.html (accessed Feb 9, 2010). Brennan MJ, Fruth U, Milstien J, Tiernan R, de Andrade NS, Chocarro L. Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med 2007; 4: e252. Minnies D, Hawkridge T, Hanekom W, Ehrlich R, London L, Hussey G. Evaluation of the quality of informed consent in a vaccine eld trial in a developing country setting. BMC Med Ethics 2008; 9: 15. Treatment Action Group. Tuberculosis research and development: 2009 report on tuberculosis research funding trends, 20052008. New York, NY: Treatment Action Group, 2009. Moran M, Guzman J, Ropars A-L, et al. Neglected disease research and development: how much are we really spending? London, UK: George Institute for International Health, 2008. Agarwal N. A critical analysis of funding trends 20052007: an update. New York, NY: Treatment Action Group, 2009. Kaufmann SHE, Parida S. Changing funding patterns in tuberculosis. Nat Med 2007; 13: 299303. GAVI Alliance and World Bank. Consultation and advisory process: advance market commitment for pneumococcal vaccines. April 20, 2009. http://www.vaccineamc.org/les/amcconsultationreportdec. pdf (accessed Feb 9, 2010). Dye C, Williams BG. Eliminating human tuberculosis in the twenty-rst century. J R Soc Interface 2008; 5: 65362. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benets of more-eective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009; 106: 1398085.

www.thelancet.com Vol 375 June 12, 2010

2119